RESERVOIR ADVISORY BOARD
Reservoir’s Advisory Board comprises leading experts at the intersection of commercial strategy, health policy, and strategic communications. Leveraging decades of experience, our Advisory Board members serve as invaluable thought partners, helping us to enhance the value we bring to the work that we do for our clients.

Mark Booth
Mark is a seasoned biopharmaceutical executive and commercial leader with extensive experience in product marketing, commercial strategy and operations, management consulting, and market research. Currently, he serves as the Head of Commercial at Verastem Oncology, where he leads the launch of avutometinib and defactinib for Low-Grade Serous Ovarian Cancer.Prior to his role at Verastem, Mark directed the Product Innovation and Monetization Practice at Real Chemistry, where he supported life sciences companies in advancing oncology and specialty treatments. He also led the Oncology and Specialty Business Unit at Kantar Health, an Oracle company, overseeing product development, syndicated assets, and custom research initiatives.Earlier in his career, Mark was the Marketing Lead at Orexigen Therapeutics, where he successfully launched Contrave. His professional journey also includes nearly two decades at Merck & Company, during which he held various roles with increasing responsibility.Mark holds a BS in Exercise Science, an MS in Cardiac Rehabilitation from Slippery Rock University of Pennsylvania, and an MBA from the University of New Hampshire.

Jenny Bryant

Laureen Cassidy

Donna Cryer

Mike Kelly

David Palombi

Orriel Richardson

Paul Rittman

Bridget Walsh
Bridget Walsh is a proven Corporate Affairs leader with extensive experience leading government and public affairs teams for Fortune 500 healthcare companies. In these roles, she demonstrated the ability to mitigate risk by engaging with key stakeholders, developing and implementing strategies that protect and enhance organizational outcomes and reputations. She is adept at cultivating positive, credible and influential relationships with numerous stakeholders, including lawmakers, trade associations and national public policy groups. Bridget currently serves on the California Life Sciences Board of Directors.